neuroendocrine tumor (NET)

You have access
Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro
Xi-Feng Jin, Christoph J. Auernhammer, Harun Ilhan, Simon Lindner, Svenja Nölting, Julian Maurer, Gerald Spöttl and Michael Orth

Journal of Nuclear Medicine September 1, 2019, 60 (9) 1240-1246; DOI: https://doi.org/10.2967/jnumed.118.224048
You have access
Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog ¹⁷⁷Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors
Jingjing Zhang, Hao Wang, Orit Jacobson, Yuejuan Cheng, Gang Niu, Fang Li, Chunmei Bai, Zhaohui Zhu and Xiaoyuan Chen

Journal of Nuclear Medicine November 1, 2018, 59 (11) 1699-1705; DOI: https://doi.org/10.2967/jnumed.118.209841
You have access
NAMPT Inhibitor GMX1778 Enhances the Efficacy of ¹⁷⁷Lu-DOTATATE Treatment of Neuroendocrine Tumors
Anna-Karin Elf, Peter Bernhardt, Tobias Hofving, Yvonne Arvidsson, Eva Forssell-Aronsson, Bo Wängberg, Ola Nilsson and Viktor Johanson

Journal of Nuclear Medicine February 1, 2017, 58 (2) 288-292; DOI: https://doi.org/10.2967/jnumed.116.177584

Main menu